Ocumension Therapeutics (FRA:5DG)

Germany · Delayed Price · Currency is EUR

0.5650

+0.0300 (5.61%)

At close: Aug 26, 2026

-45.15% (1Y)

Market Cap	479.55M -44.1%
Revenue (ttm)	97.95M +92.7%
Net Income	-19.34M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	67.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.5650
Previous Close	0.5350
Day's Range	0.5650 - 0.5650
52-Week Range	0.4300 - 1.1600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation,... [Read more]

Industry Pharmaceutical Preparations

Founded 2017

Employees 552

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 5DG

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY Financial Statements